Masso Torrence Wealth Management Inc. Has $465,000 Holdings in Johnson & Johnson (NYSE:JNJ)

view original post

Masso Torrence Wealth Management Inc. boosted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 5.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,626 shares of the company’s stock after buying an additional 131 shares during the quarter. Masso Torrence Wealth Management Inc.’s holdings in Johnson & Johnson were worth $465,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Norges Bank bought a new stake in Johnson & Johnson in the 4th quarter valued at $4,172,929,000. BlackRock Inc. boosted its holdings in Johnson & Johnson by 2.6% in the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after purchasing an additional 4,982,885 shares during the period. GQG Partners LLC boosted its holdings in Johnson & Johnson by 1,109.4% in the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after purchasing an additional 3,627,424 shares during the period. State Street Corp boosted its holdings in Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after purchasing an additional 2,492,359 shares during the period. Finally, National Bank of Canada FI bought a new stake in Johnson & Johnson in the 4th quarter valued at $286,371,000. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,161 shares of company stock worth $13,895,302. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Up 1.5 %

Shares of Johnson & Johnson stock opened at $178.23 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $468.99 billion, a P/E ratio of 24.02, a price-to-earnings-growth ratio of 3.48 and a beta of 0.63. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The company has a 50-day simple moving average of $176.76 and a 200 day simple moving average of $174.35.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, beating the consensus estimate of $2.60 by $0.07. The firm had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the company posted $2.59 EPS. Research analysts expect that Johnson & Johnson will post 10.21 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.54%. The ex-dividend date was Monday, May 23rd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.92%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on JNJ. Raymond James increased their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday, July 8th. Finally, The Goldman Sachs Group raised their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $191.29.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.